Last reviewed 2026-04-20 · How we verify

Postinor 2

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue / weakness
• Nausea
• Lower abdominal pain
• Dizziness
• Breast tenderness
• Headache
• Stomachache

Key clinical trials

• Postplacental Copper Intrauterine Device Versus Postpartum Progesterone-only Pills on Uterine Niche Formation (NA)
• A Study of Elenestinib in Healthy Adult Female Participants (PHASE1)
• A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants (PHASE1)
• Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (PHASE1)
• To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men. (PHASE1)
• Phase II Study of Ovulation in Obese Women (PHASE2)
• Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days (PHASE2)
• Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Postinor 2 CI brief — competitive landscape report
• Postinor 2 updates RSS · CI watch RSS
• Bayer portfolio CI